Anecdote: when good slides go bad
I vividly recall a January 2023 morning in my Pisa lab, sorting a fresh batch of spatial omics samples that had arrived from three hospitals; the file names promised clean metadata and clear tissue maps. The stereo-seq sample gallery entry looked perfect on screen, but when we ran sequencing we recovered usable reads from only 14 of 24 sections—what specific step cost us those ten samples? (I still shake my head at that loss.)
Why does this happen?
I’ve spent over 15 years handling tissue prep and spatial transcriptomics pipelines, and I can tell you the familiar culprits repeat: slide drying during transport, suboptimal fixation, and barcoding inconsistencies that lower effective spatial resolution. I remember one Visium-like slide (10x Genomics Visium equivalent) from a collaborator in Milan that lost 30% of expected gene counts after a four‑hour delay at room temperature; that single delay translated to weeks of repeated work. My point is plain: raw gallery images—pretty as they are—hide preanalytical flaws that standard QC flags sometimes miss. So yes, the gallery can mislead you unless you interrogate the sample provenance and sequencing metrics closely.
Transitional note: below I outline where traditional solutions fail and what I now test first.
Technical and comparative lens: where fixes must focus
I’ll be frank: many labs patch problems with quick fixes—re-running a library, tweaking aligner settings—but these measures often treat symptoms, not root causes. From a technical vantage I compare three vectors: sample integrity (RNase exposure, fixation time), spatial capture fidelity (barcode density and placement), and sequencing depth (reads per spot). When I audit a set of spatial omics samples I run a simple checklist—RIN or DV200 values, barcode collision rates, and a pilot sequencing lane at 5 million reads per sample—to expose which axis is failing. In a project last summer in Naples, applying that checklist reduced re-run rate from 40% to 12% in six weeks. That was measurable. It also revealed a less obvious pain point: mixed metadata formats from different clinics that broke automated pipelines (ugh, messy!).
What’s Next?
Going forward, labs should compare sample providers and platforms not just on price or gallery aesthetics but on quantifiable output: yield of mapped reads, median genes per spot, and consistency of barcodes across replicates. I recommend three clear evaluation metrics when choosing a workflow or sample source: 1) pre-sequencing RNA quality thresholds (set a hard DV200 > 50% or equivalent), 2) spatial capture reliability (verify barcode collision < 2% in pilot runs), and 3) effective sequencing depth (target reads per spot tied to your biological question). These metrics let you judge suppliers and protocols side-by-side—fast, concrete, non‑vague. Also, check the gallery images against raw FASTQ QC; sometimes the photos look great but the FASTQ tells the true story—trust the numbers. Finally, keep a running log (I use a shared spreadsheet) with dates, operator names, and transport times; small records avoid huge headaches later.
I’ve seen the difference firsthand: a lab that standardized those three metrics cut project delays in half. We learned to demand better sample provenance, to ask for pilot sequencing, and to prefer transparency over glossy galleries. Short pause—then act. For reliable spatial omics workflows, start with those checks, compare objectively, and keep iterating with real data. For more curated examples and references, see the spatial omics samples entries; they helped me form these checklists. I sign off here—not as an ad, but as a colleague with a hard‑won checklist—cheers, and visit stomics.